Literature DB >> 19937668

Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1.

Joana Tavares1, Ali Ouaissi, Paul Kong Thoo Lin, Inês Loureiro, Simranjeet Kaur, Nilanjan Roy, Anabela Cordeiro-da-Silva.   

Abstract

The NAD(+)-dependent deacetylases, namely sirtuins, are involved in the regulation of a variety of biological processes such as gene silencing, DNA repair, longevity, metabolism, apoptosis, and development. An enzyme from the parasite Leishmania infantum that belongs to this family, LiSIR2RP1, is a NAD(+)-dependent tubulin deacetylase and an ADP-ribosyltransferase. This enzyme's involvement in L. infantum virulence and survival underscores its potential as a drug target. Our search for selective inhibitors of LiSIR2RP1 has led, for the first time, to the identification of the antiparasitic and anticancer bisnaphthalimidopropyl (BNIP) alkyl di- and triamines (IC(50) values in the single-digit micromolar range for the most potent compounds). Structure-activity studies were conducted with 12 BNIP derivatives that differ in the length of the central alkyl chain, which links the two naphthalimidopropyl moieties. The most active and selective compound is the BNIP diaminononane (BNIPDanon), with IC(50) values of 5.7 and 97.4 microM against the parasite and human forms (SIRT1) of the enzyme, respectively. Furthermore, this compound is an NAD(+)-competitive inhibitor that interacts differently with the parasite and human enzymes, as determined by docking analysis, which might explain its selectivity toward the parasitic enzyme.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19937668     DOI: 10.1002/cmdc.200900367

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  11 in total

1.  In vitro and in vivo anticancer activity of a novel nano-sized formulation based on self-assembling polymers against pancreatic cancer.

Authors:  Clare Hoskins; Mehdi Ouaissi; Sofia Costa Lima; Woei Ping Cheng; Inês Loureirio; Eric Mas; Dominique Lombardo; Anabela Cordeiro-da-Silva; Ali Ouaissi; Paul Kong Thoo Lin
Journal:  Pharm Res       Date:  2010-09-25       Impact factor: 4.200

Review 2.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

3.  Activity of Bisnaphthalimidopropyl Derivatives against Trypanosoma brucei.

Authors:  Nuno A G Graça; Luis Gaspar; David M Costa; Inês Loureiro; Paul Kong Thoo-Lin; Isbaal Ramos; Meritxell Roura; Alain Pruvost; Ian K Pemberton; Hadjer Loukil; Jane MacDougall; Joana Tavares; Anabela Cordeiro-da-Silva
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

4.  Novel Heteroaryl Selenocyanates and Diselenides as Potent Antileishmanial Agents.

Authors:  Ylenia Baquedano; Verónica Alcolea; Miguel Ángel Toro; Killian Jesús Gutiérrez; Paul Nguewa; María Font; Esther Moreno; Socorro Espuelas; Antonio Jiménez-Ruiz; Juan Antonio Palop; Daniel Plano; Carmen Sanmartín
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 5.  Novel lead compounds in pre-clinical development against African sleeping sickness.

Authors:  Michael Berninger; Ines Schmidt; Alicia Ponte-Sucre; Ulrike Holzgrabe
Journal:  Medchemcomm       Date:  2017-07-31       Impact factor: 3.597

Review 6.  Rejuvenating sirtuins: the rise of a new family of cancer drug targets.

Authors:  Santina Bruzzone; Marco Daniele Parenti; Alessia Grozio; Alberto Ballestrero; Inga Bauer; Alberto Del Rio; Alessio Nencioni
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death.

Authors:  Despina Smirlis; Michael Duszenko; Antonio Jiménez Ruiz; Effie Scoulica; Patrick Bastien; Nicolas Fasel; Ketty Soteriadou
Journal:  Parasit Vectors       Date:  2010-11-17       Impact factor: 3.876

8.  Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease.

Authors:  Luís Gaspar; Ross P Coron; Paul KongThoo Lin; David M Costa; Begoña Perez-Cabezas; Joana Tavares; Meritxell Roura-Ferrer; Isbaal Ramos; Céline Ronin; Louise L Major; Fabrice Ciesielski; Iain K Pemberton; Jane MacDougall; Paola Ciapetti; Terry K Smith; Anabela Cordeiro-da-Silva
Journal:  PLoS Negl Trop Dis       Date:  2018-01-22

Review 9.  Sirtuins of parasitic protozoa: in search of function(s).

Authors:  Agnieszka A Religa; Andrew P Waters
Journal:  Mol Biochem Parasitol       Date:  2012-08-10       Impact factor: 1.759

10.  Ligand-based virtual screening and inductive learning for identification of SIRT1 inhibitors in natural products.

Authors:  Yunan Sun; Hui Zhou; Hongmei Zhu; Siu-wai Leung
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.